Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis

Table 2 Drug sensitivity of the isolated strains

Strain	Antibiotics												Isolated from
Strain	CLA	RIF	STFX	LVFX	EB	AMK	FRPM	DRPM	INH	MINO	IPM	TGC	Isolated from
M. fortuitum type strain	4	>32	1	≦0.25	0.5	2	64	128	4	≦1	>64	0.5	sputum
M. fortuitum #1	64	>32	0.25	≦0.25	0.5	8	2	32	4	4	>64	0.5	sputum (at referral)
M. fortuitum #2	64	>32	0.125	≦0.25	0.5	4	4	32	8	16	>64	0.5	sputum (8 months after referral)
M. fortuitum #3	32	>32	0.5	≦0.25	0.5	8	2	32	8	16	>64	0.5	sputum (14 months after referral, at the 2nd bronchoscopy)
M. fortuitum #4	128	>32	0.25	≦0.25	0.5	4	2	32	4	8	>64	0.5	sputum (18 months after referral)
M. fortuitum #5	32	>32	0.125	≦0.25	0.5	4	4	32	8	16	>64	0.5	sputum (35 months after referral)
M. fortuitum #6	32	>32	0.125	≦0.25	0.5	4	4	32	8	16	>64	0.5	sputum (38 months after referral, at the 3rd bronchoscopy)
M. fortuitum #7	32	>32	0.125	≦0.25	0.5	4	4	64	8	8	>64	0.5	intestinal fluid (38 months after referral)

The isolates were incubated with cation-adjusted Mueller-Hinton broth at 30 °C. Abbreviations: CLA clarithromycin, RIF rifampicin, STFX sitafloxacin, LVFX levofloxacin, EB ethambutol, AMK amikacin, FRPM faropenem, DRPM doripenem, INH, isoniazid, MINO minomycin, IPM imipenem, TGC tigecycline

ISSN: 1471-2334